Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

NCT01518413 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Ewing's Sarcoma Family of Tumors
Osteosarcoma
Neuroblastoma
Brain Tumors

Interventions

DRUG: sorafenib
DRUG: irinotecan

Sponsor

HMeany